Trials / Withdrawn
WithdrawnNCT03400306
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- Female
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Veliparib, capsule | capsule; 50 mg or 100 mg |
| DRUG | Veliparib, tablet | tablet; 400 mg |
| DRUG | Carboplatin | Intravenous |
| DRUG | Paclitaxel | Intravenous |
Timeline
- Start date
- 2021-11-15
- Primary completion
- 2021-11-16
- Completion
- 2021-11-16
- First posted
- 2018-01-17
- Last updated
- 2021-12-08
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03400306. Inclusion in this directory is not an endorsement.